Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy.

about

Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy.

Item

http://www.wikidata.org/entity/Q35917300

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Adverse Drug Events-based Tumo ...... ts Receiving Platinum Therapy.

@ast

Adverse Drug Events-based Tumo ...... ts Receiving Platinum Therapy.

@en

type

Item

label

Adverse Drug Events-based Tumo ...... ts Receiving Platinum Therapy.

@ast

Adverse Drug Events-based Tumo ...... ts Receiving Platinum Therapy.

@en

prefLabel

Adverse Drug Events-based Tumo ...... ts Receiving Platinum Therapy.

@ast

Adverse Drug Events-based Tumo ...... ts Receiving Platinum Therapy.

@en

P1476

Adverse Drug Events-based Tumo ...... nts Receiving Platinum Therapy

@en

P2093

Chen Wang

http://www.w3.org/2001/XMLSchema#string

Christopher G Chute

http://www.w3.org/2001/XMLSchema#string

Guoqian Jiang

http://www.w3.org/2001/XMLSchema#string

Michael T Zimmermann

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

The Cancer Genome Atlas Pan-Cancer analysis project

Integrated genomic analyses of ovarian carcinoma

The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data

A side effect resource to capture phenotypic effects of drugs

Reducing confounding and suppression effects in TCGA data: an integrated analysis of chemotherapy response in ovarian cancer.

eXtasy: variant prioritization by genomic data fusion.

Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data.

Gene prioritization through genomic data fusion.

Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.

P304

51-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P478

2015

http://www.w3.org/2001/XMLSchema#string

P50

Guoqian Jiang

P577

2015-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26306234

http://www.w3.org/2001/XMLSchema#string

P932

4525249

http://www.w3.org/2001/XMLSchema#string